Vor Biopharma (NASDAQ:VOR) Director Sells $2,730,322.41 in Stock

Vor Biopharma Inc. (NASDAQ:VOR) Director Ra Capital Management, L.P. sold 92,023 shares of the stock in a transaction dated Monday, October 20th. The shares were sold at an average price of $29.67, for a total transaction of $2,730,322.41. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Tuesday, October 21st, Ra Capital Management, L.P. sold 25,027 shares of Vor Biopharma stock. The shares were sold at an average price of $28.11, for a total transaction of $703,508.97.
• On Friday, October 17th, Ra Capital Management, L.P. sold 260,859 shares of Vor Biopharma stock. The shares were sold at an average price of $29.39, for a total transaction of $7,666,646.01.
• On Thursday, October 16th, Ra Capital Management, L.P. sold 151,803 shares of Vor Biopharma stock. The shares were sold at an average price of $29.45, for a total transaction of $4,470,598.35.
• On Wednesday, October 15th, Ra Capital Management, L.P. sold 51,363 shares of Vor Biopharma stock. The shares were sold at an average price of $30.55, for a total transaction of $1,569,139.65.

Vor Biopharma Stock Performance

Shares of NASDAQ VOR opened at $27.19 on Friday. The firm has a market cap of $186.36 million, a PE ratio of -0.10 and a beta of 2.07. Vor Biopharma Inc. has a 52 week low of $2.62 and a 52 week high of $65.80. The company has a 50-day simple moving average of $35.41.

Vor Biopharma (NASDAQ:VOR) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($43.60) EPS for the quarter, missing analysts’ consensus estimates of ($11.40) by ($32.20).

Wall Street Analyst Weigh In

VOR has been the topic of a number of recent research reports. Baird R W upgraded shares of Vor Biopharma from a “hold” rating to a “strong-buy” rating in a report on Wednesday, October 15th. Robert W. Baird upgraded shares of Vor Biopharma from a “neutral” rating to an “outperform” rating and upped their target price for the company from $20.00 to $64.00 in a report on Wednesday, October 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Vor Biopharma in a report on Friday. Stifel Nicolaus upgraded shares of Vor Biopharma from a “hold” rating to a “buy” rating and set a $55.00 target price on the stock in a report on Wednesday, September 24th. Finally, Wall Street Zen lowered shares of Vor Biopharma to a “strong sell” rating in a report on Saturday, June 28th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, three have given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $77.83.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of VOR. Jane Street Group LLC purchased a new position in shares of Vor Biopharma during the 1st quarter worth about $140,000. OMERS ADMINISTRATION Corp purchased a new position in shares of Vor Biopharma during the 1st quarter worth about $100,000. Ariose Capital Management Ltd purchased a new position in shares of Vor Biopharma during the 3rd quarter worth about $5,368,000. Goldman Sachs Group Inc. lifted its holdings in shares of Vor Biopharma by 218.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock worth $61,000 after acquiring an additional 58,247 shares during the period. Finally, XTX Topco Ltd purchased a new position in shares of Vor Biopharma during the 2nd quarter worth about $66,000. 97.29% of the stock is currently owned by hedge funds and other institutional investors.

Vor Biopharma Company Profile

Vor Biopharma, Inc, a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company’s VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.